Why Labcorp Holdings (LH) is a Top Growth Stock for the Long-Term

Company Overview - Labcorp Holdings, headquartered in Burlington, NC, is a leading healthcare diagnostics company that provides comprehensive clinical laboratory services and end-to-end drug development support [11] - In 2015, Labcorp acquired Covance, a drug development services company that offers a wide range of early-stage and late-stage product development services primarily to the pharmaceutical and biotechnology industries [11] Investment Potential - Labcorp is currently rated 3 (Hold) on the Zacks Rank, with a VGM Score of A, indicating strong potential for growth investors [12] - The company is forecasted to achieve year-over-year earnings growth of 11.9% for the current fiscal year, supported by positive revisions from analysts [12] - Eight analysts have revised their earnings estimates higher in the last 60 days for fiscal 2025, with the Zacks Consensus Estimate increasing by $0.25 to $16.30 per share [12] - Labcorp has an average earnings surprise of +2.5%, further enhancing its attractiveness to investors [12] Summary of Style Scores - Labcorp's Growth Style Score is rated A, indicating strong financial strength and a positive future outlook [12] - The combination of a solid Zacks Rank and top-tier Growth and VGM Style Scores positions Labcorp as a noteworthy option for investors [13]